Novack Jeffrey Adam sold $332K of CDNA
Novack Jeffrey Adam (Secretary and General Counsel) sold 4,096 shares of CareDx, Inc. (CDNA) at an average of $81.13 ($80.47–$83.33, $0.33M total) across 3 trades on 2026-11-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest in dollar terms and executed via a pre‑arranged plan, limiting its immediate market impact but still noteworthy for traders monitoring insider activity.
Market read
A small insider sell that may cause slight short‑term pressure on CDNA but is unlikely to move the broader market.
What to watch
Potential tax planning or diversification motives behind the 10b5‑1 execution.
Background
Form 4 filings provide the first public disclosure of insider transactions.
Ticker impact
SEC Form 4 disclosed that CareDx secretary and general counsel sold 4,096 shares for $332K via a 10b5-1 plan.
likely slight pressure as the market prices in the insider sell.
The sale size is modest ($332K) and executed under a pre‑arranged plan, limiting immediate impact but could prompt short‑term downside bias.
Market effects
Minimal; only affects CareDx shareholders.
None
None
Counterpoint
The sale may be routine and not indicative of underlying fundamentals.
Key entities
- CompanyCareDx, Inc.
Biotech firm listed on NASDAQ under ticker CDNA.
- InsiderNovack Jeffrey Adam
Secretary and General Counsel of CareDx.



